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Natural killer (NK) 1 cells are endowed with "spontaneous" cytolytic activity. They 
can be recovered from normal individuals and express an ability to lyse certain types 
of target cells (1, 2). When obtained under normal conditions, NK cells can be shown 
to represent a  cellular subset with typical morphological and surface markers distin- 
guishing them from any other classical cell type (3-5). NK cells have attracted great 
attention due to their ability to preferentially lyse malignant, compared with normal, 
cells of the same histogenetic origin  (6,  7).  Furthermore, NK cells display an ability 
to react against more primitive cells within the body, notably bone marrow stem cells 
(6)  and can function as a  major resistance barrier against bone marrow grafts (8). 
When using activated cell populations in vitro, the situation becomes complicated 
and controversial. It has been suggested that, as measured by target cell specificity in 
cytolysis, monocytic  (9)  as well as T  cell lines display NK activity. Cytolytic T  cell 
lines have  also been  reported to  lose their antigen-specific lytic ability while at  the 
same  time  acquiring  NK-like  activity  (10,  11).  In  other  situations  cell  lines  that 
behaved  like  NK  cells  have  been  obtained,  but  had  partially different  specificity 
profiles (11). Arguments have also been put forward advocating that NK cells may or 
may not express clonally derived receptors with varying specificities (12,  13). 
We  believe  that  our  present  results  together  with  those  obtained  from  binding 
studies  by  another  group  (14)  can  solve  this  by  demonstrating  the  presence,  in 
activated cells, of two receptors with different specificities for target killing. 
Materials  and  Methods 
Rats.  DA rats (RTla), BN rats (RTln), and L. BN rats (RTI") were bred and maintained 
in our own colony, 
Tumors.  PI  and  P2  sarcomas  were  induced  in  DA  rats  using  dimethylbenzanthracene 
(DMBA) as described (15). Tumors were maintained in vivo by injecting single-cell suspensions 
subcutaneously into DA rats or alternatively grown in vitro in RPMI 1640 complemented with 
10%  fetal calf serum  (FCS).  Pl-clones 9  and  10  were  established by  limiting dilution and 
selected for their susceptibility or resistance for Pl-specific cytotoxic T  cells as described (16). 
The PM tumor represents a spontaneous sarcoma from L.BN rats kept in vitro and in vivo in 
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FI~.  1.  P1 and P2 are DMBA induced sarcomas in DA rats. PM represents a spontaneous sarcoma 
in L.BN rats. P1 tumor cells were cloned and recloned by limiting dilution. Tumor cells from P1 
clone 9 are susceptible and tumor cells from P1 clone 10 are resistant to lysis by DA anti-Pl-specific 
killer T  ceils  (16).  Such cytolytic T  cells  clones are established as described under Material and 
Methods. Six different clones (1-6) were used for CML as described in Material and Methods using 
an effector/target cell ratio of 5:1. 
syngeneic animals as described for P1  and P2. The characteristics of the tumor cell lines have 
been described elsewhere  (15,  16).  The  human cell line K562  and mouse lymphoma YAC-I 
were kept in vitro using Iscove's medium complemented with  10% FCS. 
Preparation of Lymphoid Cell Suspensions and Rat T Lymphocytes.  Rats were killed over carbon 
dry  ice.  Spleen  and  lymph  nodes  were  aseptically  removed.  Single-cell  suspensions  were 
prepared in phosphate-buffered saline (PBS) (Ca  ++ and Mg  +÷ free) using a stainless steel mesh. 
Erythrocytes were lysed by hypotonic shock using 0.9 ml of distilled water for 2 s followed by 
0.1  ml of 10-times concentrated PBS. T  lymphocytes were purified on  1.5  ×  10 cm Ig anti-Ig 
columns  (17)  using sterile glass beads 80-120  mesh  (Serva,  Heidelberg,  Federal  Republic of 
Germany). 
Preparation of T Cell Growth Factor (TCGF; Concanavalin A Supernatant).  Rat spleen cells were 
cultured  in  Eagles  high  amino  acid  (EHAA)  medium  (18)  complemented  with  0.5%  fresh 
normal BN rat serum and 5 X  10  -~ M  2-mercaptoethanol (2-ME) and stimulated with 5/~g/ml 
of concanavalin  A  (Pharmacia  Fine  Chemicals,  Uppsala,  Sweden).  40  ml  of a  suspension 
containing 5 X  l0  s cells per ml were cultured in a  3024 Falcon tissue tissue culture flask (Falcon 
Labware,  Div. of Becton, Dickinson & Co., Oxnard, CA), and the supernatant was harvested 
48 h  later. 
Restimulation of  Primed DA T Lymphocytes with Antiidiotypic Antibodies.  DA rats were immunized 
by  six  subcutaneous  injections  of 2  ×  107  12,500-rad  irradiated  P1  sarcoma  cells  at  2-wk 
intervals.  T  lymphocytes  from  primed  rats  were stimulated  with  antiidiotypic antibodies in 
3013 Falcon tissue culture flasks using EHAA medium complemented with 5  ×  10  -s M  2-ME 
and 0.5%  fresh normal BN rat serum  as described  (15).  Antiidiotypic antiserum was used at 1254  TWO  RECEPTORS  ALLOW  SELECTIVE  TARGET  LYSIS  BY  T  CLONES 
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FIG.  2.  DA anti-P cytolytic T cell clones  1-6 were confronted with 5~Cr-labeled target cells of P I 
clone 9 (A) at an effector/target cell ratio of 5: i. Unlabeled tumor cells from P1 clone 9 were used 
for cold target inhibition at ratios of cold/hot target of 100:1 (B), 50:1 (C), 25:1 (D), and  1:1  (E). 
The same type of experiment was performed using  unlabeled cells from P1  clone 10 at  ratios  of 
100:l  (F), 50:l  (G), 25:1 (H), and 1:1  (I). 
concentrations of 0.2%.  Each flask contained 15 ml of a suspension containing 1.25  X  106 cell/ 
m[. 
Clonzng ofPl-specific Cytotoxic T Cells.  In vitro restimulated DA T  lymphocytes (see above) 
were collected on day 6 of culture and purified over Ficoll-Paque (19).  Cells were expanded on 
DA  macrophages and  TCGF  in  the  following way:  Macrophages were harvested from  the 
peritoneal  cavity  of DA  rats,  washed  once,  and  irradiated  with  2,500  rad.  Macrophages 
obtained from one rat were distributed over three 3013  tissue culture flasks and cultured in 5 
ml EHAA-medium complemented with  10% FCS, 5  X  10  -5 M  2-ME, and 20% TCGF for 24 
h.  10  ml  of a  suspension containing  1.25  ×  106  purified restimulated T  cells  (see above)  in 
EHAA  medium complemented with  10%  FCS,  20%  TCGF,  5  X  10 -~  M  2-ME,  and  0.05% 
antiidiotypic antiserum was added to each flask. Cells were harvested 1 wk later and cloned 
and recloned on syngeneic macrophages by limiting dilution (16). Cytotoxic clones were selected 
and expanded as described above. 
Cell-mediated Cytotoxicity Assay  (CML).  CML was performed in round-bottomed microtiter 
plates  (Cook  M24  ART;  Greiner, Nuertingen, Germany)  in  200  /11  EHAA medium comple- 
mented with  5  ×  10 -~  M  2-ME  and  5%  heat-inactivated FCS.  Assays were  performed in 
triplicates with effector/target cell ratios as indicated in Figures using  104 SICr-labeled target 
cells. The latter were prepared as described previously (16).  Plates were incubated for 6  h  at 
37°C in 5% CO2 in air.  100/tl of the supernatant was counted in the gamma counter. Percent 
cytotoxicity is  expressed as  100  ×  [(experimental -  spontaneous ~lCr  release)/(maximal - 
spontaneous 5iCr release)]. 
Preparation of Antiidiotypic Antisera in DA Rats.  DA anti-Pl-specific antibodies were purified 
on paraformaldehyde-fixed  P1 sarcoma cells as described previously (15). 4 mg of purified anti- 
P 1 antibody was cross-linked with glutaraldehyde and injected together with complete Freund's 
adjuvant into 10 DA rats as described (20).  The antiidiotypic nature of the harvested sera was H.  BINZ,  M.  FENNER,  D.  FREI,  AND  H.  WIGZELL 
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Fro.  3.  Same type of experiment as described in the legend to Fig. 2, T  cell clones 1-6 were tested 
against ~lCr-labeled tumor cells from P] clone 9 (A). Unlabeled K562 tumor cells were used for cold 
target inhibition at ratios of cold/hot target of 100:1  (B), 50:1  (C), 25:1  (D), and  1:1  (E).  YAC-I 
cells were used for cold target inhibition at ratios of 100:1  (F), 50:1  (G), 25:1  (H), and 1:1  (I). 
determined by a solid-phase radioimmunoassay or by the restimulation assay using Pl-primed 
DA T  lymphocytes (15). 
Results  and  Discussion 
Our system involves the use of DMBA-induced sarcomas in DA rats, which allows 
the induction  of tumor-specific T  cell clones as well  as production of corresponding 
auto-antiidiotypic antibodies  (15).  Such antibodies  used at low concentration in the 
presence of TCGF can be used to selectively maintain  specific T  cell clones in vitro. 
In this system we have isolated six different T  cell clones, all with idiotypic receptors 
and specific lytic ability for the relevant tumor (see Fig.  1). Two of these six clones, in 
addition,  display  a  lytic profile identical  to rat  NK cells  (see  Fig.  1).  This  NK-like 
activity of clones  1 and  2 developed  gradually during in vitro culture  (16)  and was 
discovered by specificity controls. Using cold target inhibition in a crisscross manner, 
we tested whether the very same cells in clones 1 and 2 display cytotoxic T  lymphocyte 
(CTL) as well as NK specificity. Data shown in Figs. 2, 3, and 4 demonstrate that this 
is true.  Two NK targets,  YAC-1 and K562, block clone  1 and 2  (but  not clone 3-6) 
effector cells from lysing the T  cell-sensitive DA tumor P 1-clone 9, It is of importance 
that  Pl-clone 9  target  cells  are  resistant  to normal  splenic  NK cells  (see  Fig.  5).  In 
complete  correspondence,  P 1-clone 9  targets  could  block the  ability  of T  killer  cell 
clones  1 and 2 to lyse either YAC-1 or K562 target cells (see Fig. 4). 
It was crucial to establish whether clone  1 and 2 effector cells were using the same 
receptors to recognize the tumor-specific antigens on Pl-clone 9 targets as those used 
to  bind  to  YAC-1  or  K562  cells.  To  answer  this  question  we  used  antiidiotypic 1256 
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FIG. 4.  Pl-specific  cytotoxic DA T cell clones 1-6 were tested against 51Cr-labeled YAC-1 (A) 
(upper) and K562 (K) (lower) tumor cells. Tumor cells from P1 clones 9 and 10 were used for cold 
target inhibition. Unlabeled tumor cells fi'om PI clone 9 were used at ratios of 100:1 (B, L), 50:1 
(C, M), 25: i (D, N), and 1:1 (E, O). The same type of experiment at the same ratios was performed 
using cold targets from PI clone 10. 100:1 (F, P), 50:1 (G, Q), 25:1 (H, R), and 1:1 (I, S). 
antibodies in the presence or absence of complement (Fig. 6). Such antibodies in the 
presence of complement did wipe out all cytolytic activity in the clones regardless of 
the  target  type  analyzed.  However,  at  high  concentration and  in  the  absence  of 
complement, a  clear-cut selectivity of inhibition as to target  type became apparent. 
Thus, clones 1 and 2 became inhibited in their reactions to P1 clone 9 targets (like the 
other clones), but were not suppressed at all in their reactivity towards the NK targets 
YAC-1  and K562. This strongly suggests the simultaneous presence of two  distinct 
physically independent receptor  types  on  clone  1 and  2  killer T  cells:  one  that  is 
idiotypic and antigen specific, and another displaying the binding profile of NK cells. 
Our  results  demonstrate  the  possibility of  the  simultaneous expression  of  two 
distinct  lytic systems  with  different  specificities in  the  same  T  cell.  Such  parallel 
display may of course yield combined specificity profiles endowing the individual cell 
with a  selectivity distinct from most normal CTL or NK cells. This could thus well 
explain existing controversies as to the specificities encountered when using immune- 
activated effector cells (21). 
A  second note of interest is the ability of these "double-expressing" T  cells to lyse 
target  cells  (K562)  devoid  of major  histocompatibility complex  (MHC)  antigens. 
Conventional cytolytic T  cells normally fail to kill MHC-lacking targets, e.g., terato- 
carcinoma cells  (22)  and an NK-like receptor may be necessary here to allow such 
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Fzc.  5.  Spleen cells  from DA rats were used as a  source of NK cells. They were confronted for 6 
h with 51Cr-labeled  P1  and P2 sarcoma ceils and cells from P1  clones 9 and  10 as well as with PM 
tumor cells at effector/target cell ratios of 100:1 (open columns) and 50:1 (W).  NK cells were also 
tested against the classical  NK targets YAC-1  (A) and K562  (A) under the same conditions. Lyric 
capacity  against  YAC-I  and  K562  targets  was also  tested  in  the  presence of 3%  antiidiotypic 
antiserum of specificity  DA anti-(DA anti@l)  (15,  16)  (B) or 3% DA normal serum (C). 
lysis to occur.  Whether such  a  receptor will  indeed  act  as a  triggering unit  for the 
induction of a potential lytic machinery, like the IgG antibodies in antibody-depend- 
ent cellular cytotoxicity systems (23), is an important issue. Recent studies  (14)  have 
indicated  that the ability to express an NK-like binding specificity is a  feature that 
can be found on several types of bone marrow-derived cells. Our findings should thus 
not be considered as evidence for the inclusion of the conventional  NK cells within 
the T  cell lineage. The combination of lytic ability and NK binding specificity may, 
therefore, in a  normal situation,  be something uniquely restricted to the distinct cell 
type classically defined  as an  NK cell.  Situations  leading  to the  induction  of lytic 
capacities in normally nonlytic cells may thus create an NK-like activity in non-NK 
effector cell types. Depending on the frequency of cells expressing NK-binding activity 
in such populations, one should expect the appearance, upon activation, of cells with 
dual specificities in the manner reported in this study. 
SuF[llTlary 
Dimethylbenzanthracene-induced  P1  sarcoma cells  induce  Pl-specific antibodies 
in syngeneic DA rats.  Antiidiotypic  antibodies  of specificity DA anti-(DA  anti-P1) 
were induced against the tumor-specific antibodies and used to restimulate P l-primed 
DA T  cells  in  vitro.  Using  antiidiotypic  antibodies  and  T  cell  growth  factor,  P1- 
specific cytotoxic DA T  cell clones were established by limiting dilution and kept in 
vitro.  Two  of these  clones  acquired  during  culture  periods  in  addition  to  the  P1 
specificity lytic activity towards  natural  killer  (NK)  targets YAC-1  or K562.  Cold 1258  TWO  RECEPTORS  ALLOW  SELECTIVE  TARGET  LYSIS  BY  T  CLONES 
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Fro.  6.  DA anti-P1  cytotoxic T  cell clones (1-6)  were used as effector cells at an effector/target 
cell ratio of 5:1.  (A) Targets, Pl sarcoma cells; effector cell untreated; (B) Targets, P1 sarcoma cells; 
effector cells treated with  1:10 diluted DA anti-(DA anti-P1) antiidiotypic antiserum and comple- 
ment (21).  (C) Targets, P1 sarcoma cells; effector cells treated with 1:10 diluted normal DA serum 
and complement. (D)  Targets, tumor cells from P1  clone 9;  effector cells untreated.  (E)  Targets, 
tumor cells from Pl clone 9; effector cells treated with antiidiotypic antiserum and complement (see 
B).  (F)  Targets,  tumor cells from  P1  clone 9;  effector cells treated with  normal  DA serum and 
complement. ((3) Targets, tumor cells fi'om P1  clone 9;  3% of antiidiotypic antiserum was present 
during test period. (H) Targets, tumor cells from P1 clone 9; 3% ofantiidiotypic antiserum absorbed 
on Pl specific DA T  cell clones 1-6 was present during test period. (1) Targets, YAC-1; effector cells 
untreated. (K) Targets, YAC-l; effector cells treated with antiidiotypic antiserum and complement. 
(L)  Targets, YAC-1; effector cells treated with normal DA serum and complement. (M)  Targets, 
YAC-1;  3%  of antiidiotypic antiserum  was  present during  test  period.  (N)  Targets,  YAC-1;  3% 
absorbed (see H)  antiidiotypic antiserum was present during test period. (O) Targets, YAC-1; 3% 
normal DA serum was present during test period. (P) Targets, K562; effector cells untreated. (O) 
Targets,  K562;  effector cells treated with antiidiotypic antiserum and complement. (R)  Targets, 
K562;  effector cells treated with  DA  normal  serum and complement. (S)  Targets,  K562;  3% of 
antiidiotypic  antiserum  was  present  during  test  period.  (T)  Targets,  K562;  3%  of  absorbed 
antiidiotypic antiserum was present during test period. (U) Targets, K562; 3% of normal DA serum 
was present during test period. 
34561 
target  inhibition  experiments  showed  that  the very same  cytotoxic  T  cells kill  P1  and 
NK  targets.  Antiidiotypic  antibodies  of specificity  DA  anti-(DA  anti-P1)  inhibited 
cytotoxicity  against  P l  but  not  against  YAC-1  or  K562.  We  conclude  that  two 
independent  receptors  are  located  on  these double-reactive  T  cell  clones, one  that  is 
idiotypic  and  antigen-specific,  and  another  displaying  the binding  profile of NK  cells. 
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